文献速递慢阻肺肺结节与肺癌

肺癌筛查人群中气流受限与肺气肿的患病率:系统综述与荟萃分析

Prevalence of Airflow Limitation and Emphysema in Lung Cancer Screening Populations: A Systematic Review and Meta-Analysis.
PubMed 文献 · Chest · 2025-03-05

该系统综述与荟萃分析纳入42项原始研究,评估肺癌筛查参与者中CT确诊肺气肿和肺功能确诊气流受限的患病率。结果显示肺气肿合并患病率为45.3%,气流受限为40.1%,其中65.2%的气流受限患者此前未被识别。提示将肺功能检查纳入筛查项目可能提高COPD的检出与管理。

要点

  • 肺癌筛查人群中肺气肿患病率45.3%,气流受限患病率40.1%。
  • 气流受限患者中65.2%此前未被识别,提示诊断不足。
  • 将肺功能检查纳入肺癌筛查可能改善COPD检出。

核心结论

  • 肺癌筛查参与者中肺气肿患病率45.3%,气流受限患病率40.1%,其中65.2%的气流受限此前未被识别。
  • 将肺功能检查纳入筛查项目可能增强COPD的检出与管理。

研究设计与样本

  • 系统综述与荟萃分析,检索Ovid-MEDLINE和Embase数据库从建库至2023年11月30日。
  • 纳入报告CT确诊肺气肿和/或肺功能确诊气流受限患病率的原始研究,共42项(肺气肿18项,气流受限13项,两者11项)。
  • 肺气肿分析纳入126,842人,气流受限分析纳入72,209人。

主要发现

  • 肺气肿合并患病率为45.3%(95%CI,39.3%-51.2%)。
  • 气流受限合并患病率为40.1%(95%CI,33.4%-46.8%)。
  • 肺气肿患者中28.8%为中重度(95%CI,24.2%-33.4%)。
  • 气流受限患者中54.3%为中重度至极重度(95%CI,40.6%-60.6%)。
  • 65.2%的气流受限患者此前未被识别(95%CI,55.7%-74.7%)。

临床怎么用

  • 在肺癌筛查中考虑纳入肺功能检查,以提高气流受限的检出率。
  • 对筛查发现的肺气肿和气流受限患者,应评估严重程度并启动COPD管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early detection and treatment of COPD are becoming important for improving the prognosis of individuals who have a history of heavy tobacco use. Despite the higher risk of COPD among individuals participating in lung cancer screening, many of these patients continue to show rates of underdiagnosis of lung cancer. RESEARCH QUESTION: How many participants in lung cancer screening have emphysema or airflow limitation? If spirometry is incorporated into the screening, how many additional patients with airflow limitation could be identified? STUDY DESIGN AND METHODS: The Ovid-MEDLINE and Embase databases were searched from inception through November 30, 2023. We included original studies reporting the prevalence of CT scan-confirmed emphysema and spirometry-confirmed airflow limitation. The primary outcomes were the prevalence of emphysema and airflow limitation. For studies reporting severity, we analyzed the percentage of mild vs moderate to severe disease. We also calculated the proportion of newly confirmed cases of airflow limitation via spirometry. RESULTS: In total, 42 studies were included (emphysema, n = 18; airflow limitation, n = 13; both, n = 11), comprising 126,842 individuals with emphysema and 72,209 individuals with airflow limitation. The pooled prevalence of emphysema was 45.3% (95% CI, 39.3%-51.2%), and that of airflow limitation was 40.1% (95% CI, 33.4%-46.8%). Moderate to severe emphysema was observed in 28.8% of patients with emphysema (95% CI, 24.2%-33.4%), whereas 54.3% patients with airflow limiation (95% CI, 40.6%-60.6%) showed moderate to very severe airflow limitation. Furthermore, 65.2% of patients with airflow limitation (95% CI, 55.7%-74.7%) identified by spirometry had been unrecognized previously. INTERPRETATION: Among screening participants, 45.3% demonstrated emphysema and 40.1% demonstrated airflow limitation, with 28.8% and 54.3% of these patients showing moderate to severe disease, respectively. Furthermore, 65% of patients with airflow limitation had not received a diagnosis previously. These findings suggest that incorporating spirometry into screening programs may enhance COPD detection and management. CLINICAL TRIAL REGISTRY: International Prospective Register of Systematic Reviews; No.: CRD42024513248; URL: https://www.crd.york.ac.uk/prospero/.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Choi H, Kwak IY, Oh CR, et al. Prevalence of Airflow Limitation and Emphysema in Lung Cancer Screening Populations: A Systematic Review and Meta-Analysis. Chest. 2025. PMID: 40054601. doi:10.1016/j.chest.2025.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。